Literature DB >> 8873541

Reduction of isoflurane minimal alveolar concentration by remifentanil.

E Lang1, A Kapila, D Shlugman, J F Hoke, P S Sebel, P S Glass.   

Abstract

BACKGROUND: Remifentanil is a new micro-specific opioid receptor agonist currently under investigation. The interaction between opioids and volatile anesthetics is complex. Defining this interaction provides a basis for more rational dosing schemes when such combinations are used for anesthesia and allows the anesthetic potency of remifentanil relative to other opioids to be determined.
METHODS: Two centers enrolled a total of 220 patients. Patients were randomized to receive a target concentration of remifentanil via a computer-assisted continuous infusion device of either 0.0, 0.5, 1.0, 1.5, 2.0, 4.0, 8.0, 16.0, and 32.0 ng/ml initiated before the administration of isoflurane. Patients were also stratified by groups 18-30, 31-55, and 56-65 yr. After induction of anesthesia with isoflurane the initial patient in each dose group was assigned an age-adjusted isoflurane concentration. The isoflurane concentration for each subsequent patient was adjusted according to the up/down technique until a minimum of 12 patients were enrolled in each group. Arterial blood samples for remifentanil whole blood concentrations were obtained. The patient was observed for purposeful movement for up to 1 min after skin incision. The minimum alveolar concentration (MAC) of isoflurane (0 ng/ml remifentanil group) and MAC reduction of isoflurane by remifentanil were determined.
RESULTS: The MAC of isoflurane alone was 1.3%. Remifentanil caused an exponential reduction in the MAC of isoflurane with 1.37 ng/ml remifentanil a 77% reduction and 32 ng/ml a 91% reduction of isoflurane MAC.
CONCLUSION: The MAC reduction of isoflurane by remifentanil is similar to that produced by other opioids. Although remifentanil was given at extremely high concentrations in the absence of isoflurane, it did not provide adequate anesthesia. A 50% isoflurane MAC reduction is produced by 1.37 ng/ml remifentanil whole blood concentration compared to previously published plasma concentrations of fentanyl of 1.67 ng/ml or sufentanil of 0.14 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873541     DOI: 10.1097/00000542-199610000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  27 in total

1.  Evaluation of two new ecological interface approaches for the anesthesia workplace.

Authors:  A Jungk; B Thull; A Hoeft; G Rau
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

Review 2.  Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  [Pharmacokinetic-pharmacodynamic models for inhaled anaesthetics].

Authors:  S Kreuer; J Bruhn; W Wilhelm; T Bouillon
Journal:  Anaesthesist       Date:  2007-06       Impact factor: 1.041

4.  Monitoring the nociception level: a multi-parameter approach.

Authors:  Nir Ben-Israel; Mark Kliger; Galit Zuckerman; Yeshayahu Katz; Ruth Edry
Journal:  J Clin Monit Comput       Date:  2013-07-09       Impact factor: 2.502

Review 5.  The clinical pharmacology of remifentanil: a brief review.

Authors:  Talmage D Egan
Journal:  J Anesth       Date:  1998-12       Impact factor: 2.078

Review 6.  Spotlight on remifentanil for general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Propofol combined with remifentanil reduces the adverse reactions of patients undergoing laparoscopic cholecystectomies.

Authors:  Juhui Chen; Xiaogang Ying; Danfeng Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  Population pharmacokinetics of remifentanil in infants and children undergoing cardiac surgery.

Authors:  Wai Johnn Sam; Gregory B Hammer; David R Drover
Journal:  BMC Anesthesiol       Date:  2009-07-27       Impact factor: 2.217

9.  An evaluation of remifentanil-sevoflurane response surface models in patients emerging from anesthesia: model improvement using effect-site sevoflurane concentrations.

Authors:  Ken B Johnson; Noah D Syroid; Dhanesh K Gupta; Sandeep C Manyam; Nathan L Pace; Cris D LaPierre; Talmage D Egan; Julia L White; Diane Tyler; Dwayne R Westenskow
Journal:  Anesth Analg       Date:  2009-10-09       Impact factor: 5.108

10.  Response surface model predictions of emergence and response to pain in the recovery room: An evaluation of patients emerging from an isoflurane and fentanyl anesthetic.

Authors:  Noah D Syroid; Ken B Johnson; Nathan L Pace; Dwayne R Westenskow; Diane Tyler; Frederike Brühschwein; Robert W Albert; Shelly Roalstad; Samuel Costy-Bennett; Talmage D Egan
Journal:  Anesth Analg       Date:  2010-08       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.